At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CLRB Cellectar Biosciences
Closed 09-28 16:00:00 EDT
1.83
+0.03
+1.67%
盘后1.78
-0.05-2.73%
19:30 EDT
High1.89Low1.80Vol65.02K
Open1.80D1 Closing1.80Amplitude5.01%
Mkt Cap17.30MTradable Cap16.49MTotal Shares9.45M
T/O120.49KT/O Rate0.72%Tradable Shares9.01M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Cellectar BioSciences Publishes Corporate Presentation on Phospholipid Drug Conjugate Oncology Platform, Iopofosine I-131 Program
Reuters  ·  08-19
Cellectar BioSciences Publishes Corporate Presentation on Phospholipid Drug Conjugate Oncology Platform, Iopofosine I-131 Program
Cellectar Biosciences reports Q2 EPS (57c), consensus (52c)
TIPRANKS  ·  08-17
Cellectar Biosciences reports Q2 EPS (57c), consensus (52c)
Cellectar’s New Phase 3 WM Trial Puts Iopofosine I 131 on Investors’ Radar
TIPRANKS  ·  08-15
Cellectar’s New Phase 3 WM Trial Puts Iopofosine I 131 on Investors’ Radar
Stempoint Capital Lp Reports 9.9% Passive Stake in Cellectar Biosciences Inc as of June 30- SEC Filing
THOMSON REUTERS  ·  08-15
Stempoint Capital Lp Reports 9.9% Passive Stake in Cellectar Biosciences Inc as of June 30- SEC Filing
Inhibrx Biosciences Q2 Net Loss Widens on Higher Expenses
Reuters  ·  08-14
Inhibrx Biosciences Q2 Net Loss Widens on Higher Expenses
Cellectar Biosciences Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-13
Cellectar Biosciences Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Cellectar Biosciences Q2 Net Income USD -6.9 Million
THOMSON REUTERS  ·  08-13
Cellectar Biosciences Q2 Net Income USD -6.9 Million
Cellectar Biosciences - Initiates Site Activation for Phase 3 Iopfosine I 131 Study; Nda Submission Planned Mid-2027
THOMSON REUTERS  ·  08-13
Cellectar Biosciences - Initiates Site Activation for Phase 3 Iopfosine I 131 Study; Nda Submission Planned Mid-2027
Cellectar Biosciences Q2 EPS USD -0.57
THOMSON REUTERS  ·  08-13
Cellectar Biosciences Q2 EPS USD -0.57
Cellectar Biosciences - Reports Cash and Cash Equivalents of $34 Mln as of June 30, 2026
THOMSON REUTERS  ·  08-13
Cellectar Biosciences - Reports Cash and Cash Equivalents of $34 Mln as of June 30, 2026
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
THOMSON REUTERS  ·  08-13
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Cellectar BioSciences FY26 Q2 Net Loss Widens to About $12.6 Million; R&D Expense Rises 91% to About $4.56 Million vs FY25 Q2
Reuters  ·  08-13
Cellectar BioSciences FY26 Q2 Net Loss Widens to About $12.6 Million; R&D Expense Rises 91% to About $4.56 Million vs FY25 Q2
Cellectar Biosciences Q2 EPS $(0.57) Misses $(0.48) Estimate
Benzinga Earnings  ·  08-13
Cellectar Biosciences Q2 EPS $(0.57) Misses $(0.48) Estimate
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  08-13
Calendar of U.S. Earnings Expected in the Week Ahead
Cellectar Biosciences Inc Expected to Post a Loss of 48 Cents a Share - Earnings Preview
Reuters  ·  08-11
Cellectar Biosciences Inc Expected to Post a Loss of 48 Cents a Share - Earnings Preview
Cellectar BioSciences Schedules Quarterly Results Conference Call
Reuters  ·  07-30
Cellectar BioSciences Schedules Quarterly Results Conference Call
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
GlobeNewswire  ·  07-30
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
Cellectar Biosciences Publishes Corporate Presentation on Phospholipid Drug Conjugate Radiotherapy Pipeline, Led by Iopofosine I-131 in Waldenstrom Macroglobulinemia
Reuters  ·  07-21
Cellectar Biosciences Publishes Corporate Presentation on Phospholipid Drug Conjugate Radiotherapy Pipeline, Led by Iopofosine I-131 in Waldenstrom Macroglobulinemia
Cellectar Reports Phase 1 Study Publication Supports Iopofosine I-131 Potential in Relapsed Multiple Myeloma
Reuters  ·  07-15
Cellectar Reports Phase 1 Study Publication Supports Iopofosine I-131 Potential in Relapsed Multiple Myeloma
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
GlobeNewswire  ·  07-15
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

Introduction

Company Name.
Cellectar Biosciences
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Issue price:
--